Canakinumab Clinical Trials

4 actively recruiting trials across 3 locations

▲ +1 trial since June 2026

Also known as: ACZ885, Ilaris

Pipeline

Phase 2: 4

Top Sponsors

M.D. Anderson Cancer Center2
Uma Borate1
NYU Langone Health1

Indications

Cancer3
Rheumatic Disease1
Clonal Cytopenia of Undetermined Significance1
Refractory Myelodysplastic Syndrome1
Lupus1

Houston, Texas2 trials

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

M D Anderson Cancer Center

Phase 2

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M D Anderson Cancer Center

Phase 2

Miami, Florida1 trial

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

University of Miami

Phase 2

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.